Sung Hae Kim, JuHee Lee
Development and psychometric evaluation of the adjuvant endocrine therapy beliefs scale for breast cancer survivors
Archives of women's mental health
data costeffectiveness firstline infliximab paediatric patients crohns disease limited since biologics increasingly prescribed accompanied high costs knowledge gap needs addressed investigate costeffectiveness firstline infliximab compared conventional treatment children moderatetosevere crohns disease included patients topdown infliximab study kids crohns disease randomised controlled trial children newly diagnosed moderatetosevere crohns disease treated azathioprine maintenance either five induction infliximab biosimilar infusions conventional induction treatment exclusive enteral nutrition corticosteroids direct healthcare consumption costs obtained per patient week 104 included data outpatient hospital visits hospital admissions drug costs endoscopies surgeries primary health outcome odds ratio clinical remission weighted paediatric crohns disease activity index125 104 weeks included 89 patients 44 firstline infliximab group 45 conventional treatment group mean direct healthcare costs per patient 36784 firstline infliximab treatment 36874 conventional treatment 2 years p 0981 odds ratio firstline infliximab versus conventional treatment clinical remission 104 weeks 156 95ci 103235 p 0036 firstline infliximab treatment resulted higher odds clinical remission without expensive making dominant strategy conventional treatment first 2 years diagnosis children moderatetosevere crohns disease nct02517684